Celemics, Inc. engages in the provision of biotechnology services. It operates through Next Generation Sequencing (NGS) Services and Consumable Products businesses. The NGS Services business offers whole genome, whole exome, targeted, and other sequencing. The company was founded in October 2010 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company